Shinji Yamashita

Dr. Shinji Yamashita


Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2000 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
SYShinji Yamashita
Shinji Yamashita
TFTomoyuki Furubayashi
Tomoyuki Furubayashi
MKMakoto Kataoka
Makoto Kataoka
TSToshiyasu Sakane
Toshiyasu Sakane
HSHitoshi Sezaki
Hitoshi Sezaki
HTHideaki Tokuda
Hideaki Tokuda

1 March 2002 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
SYShinji Yamashita
Shinji Yamashita
KKKeisuke Konishi
Keisuke Konishi
YYYukako Yamazaki
Yukako Yamazaki
YTYoko Taki
Yoko Taki
TSToshiyasu Sakane
Toshiyasu Sakane
YFYukihiro Furuyama
Yukihiro Furuyama

12 August 2010 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
RTRyusuke Takano
Ryusuke Takano
NTNoriyuki Takata
Noriyuki Takata
RSRyoichi Saito
Ryoichi Saito
KFKentaro Furumoto
Kentaro Furumoto
SHShoichi Higo
Shoichi Higo
SYShinji Yamashita
Shinji Yamashita

6 February 2014 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
HHHaruki Higashino
Haruki Higashino
THTsubasa Hasegawa
Tsubasa Hasegawa
MYMari Yamamoto
Mari Yamamoto
RMRie Matsui
Rie Matsui
YMYoshie Masaoka
Yoshie Masaoka
SYShinji Yamashita
Shinji Yamashita

1 June 2016 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
NHNozomi Hisada
Nozomi Hisada
RTRyusuke Takano
Ryusuke Takano
NTNoriyuki Takata
Noriyuki Takata
KSKoji Shiraki
Koji Shiraki
TUTakamitsu Ueto
Takamitsu Ueto
SYShinji Yamashita
Shinji Yamashita

13 January 2011 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
SYShinji Yamashita
Shinji Yamashita
TTTadayuki Takashima
Tadayuki Takashima
MKMakoto Kataoka
Makoto Kataoka
HOHiroyuki Oh
Hiroyuki Oh
SSShinji Sakuma
Shinji Sakuma
YWYasuyoshi Watanabe
Yasuyoshi Watanabe
This study assessed the process of gastrointestinal drug absorption in vivo using PET. Methods: 18F-FDG was used as a model probe and was orally administered to rats as a solution. PET scans were obtained of the whole body and abdominal region under conscious and anesthetized conditions. Blood samples were routinely taken from the femoral vein during scanning. The rate of gastric emptying and intestinal absorption of 18F-FDG was estimated from the time profiles of radioactivity in the stomach and small intestine. In addition, nonradiolabeled 2-fluoro-2-deoxy-d-glucose (2-FDG) was used in an intestinal closed-loop experiment to compare the intestinal permeability of 2-FDG with that of d-glucose. Results: In conscious rats, gastrointestinal absorption of 18F-FDG was rate-limited by the process of intestinal membrane permeation, because the permeability of 2-FDG through the intestinal membrane was low compared with that of d-glucose. In anesthetized rats, the gastric emptying rate of 18F-FDG decreased dramatically whereas the intestinal absorption rate constant was not significantly different from that in conscious rats. As a result, the rate-limiting step of gastrointestinal absorption of 18F-FDG was shifted to the gastric emptying process by anesthesia. Conclusion: PET technology is a powerful tool for in vivo analysis of the gastrointestinal absorption of orally administered drugs.